Skip to main content

Table 2 Survival Outcomes

From: Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada

 Historical Controls
N = 140
2nd line Ipilimumab
N = 189
Median follow-up months, (95% CI)30.4 (27.9–37.3)71.2 (70.3–116.5)
1-year survival rates, (95% CI)
 Unadjusted17.1% (11–23%)34.3% (27–41%)
 IPTW-adjusted17.1% (11–23%)35.6% (27–43%)
2-year survival rates, (95% CI)
 Unadjusted7.1% (2.9–11%)20.6% (15–27%)
 IPTW-adjusted7.1% (2.9–11%)21.1% (14–28%)
3-year survival rates, (95% CI)
 Unadjusted4.7% (1.2–8.2%)15.2% (9.6–21%)
 IPTW-adjusted4.7% (1.2–8.2%)14.3% (8.0–21%)